Pier Capital’s Emergent Biosolutions EBS Stock Holding History

Pier Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-64,274	Closed	-$5.97M	–	119
2021 Q1	$5.97M	Sell	64,274 -45,512	-41%	-$4.66M	0.57%	89
2020 Q4	$9.84M	Buy	109,786 +30,486	+38%	+$2.8M	1.04%	50
2020 Q3	$8.19M	Buy	79,300 +27,712	+54%	+$2.99M	1.2%	17
2020 Q2	$4.08M	Sell	51,588 -42,015	-45%	-$3.13M	0.65%	88
2020 Q1	$5.42M	Sell	93,603 -8,376	-8%	-$483K	1.2%	35
2019 Q4	$5.5M	Sell	101,979 -28,594	-22%	-$1.55M	0.9%	63
2019 Q3	$6.83M	Sell	130,573 -17,906	-12%	-$834K	1.16%	45
2019 Q2	$7.17M	Buy	148,479 +38,033	+34%	+$1.82M	1.11%	47
2019 Q1	$5.58M	Buy	110,446 +57,254	+108%	+$3.38M	0.87%	72
2018 Q4	$3.15M	Sell	53,192 -79,848	-60%	-$5.15M	0.63%	86
2018 Q3	$8.76M	Buy	+133,040	New	+$7.76M	1.11%	34

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pier Capital's EBS Position: Q2 2021 in Review

Pier Capital sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 64,274 shares — an estimated $5.97M sold.

Pier Capital first reported a position in EBS in Q3 2018 and held it in 11 quarters. The position peaked at $9.84M in Q4 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

Pier Capital reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
Pier Capital sold 64,274 Emergent Biosolutions shares in Q2 2021, an estimated $5.97M.
Pier Capital first reported a position in Emergent Biosolutions in Q3 2018 and held it in 11 quarters.
Pier Capital's Emergent Biosolutions position peaked at $9.84M in Q4 2020.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Pier Capital's 13F filing for Q2 2021, filed 12 Aug 2021.